Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...

An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The drug, ceftobiprole ...

Staphylococcus aureus bacteremia represents a critical bloodstream infection that demands rapid recognition and a coordinated therapeutic approach. Following the detection of S. aureus in blood ...

The Data Safety Monitoring Board (DSMB) has recommended that ContraFect’s CFRX on going DISRUPT trial be stopped because the conditional power of the study was below the pre-specified threshold for ...

In this randomized trial, dalbavancin didn't result in improved outcomes versus standard treatment for adults with complicated Staphylococcus aureus bacteremia. Rates of adverse events leading to ...

Australian researchers have uncovered new genetic insights into Staphylococcus aureus, revealing what makes the bacterium so dangerous when it enters the blood. While common, Staphylococcus aureus ...

Plus, who is at the highest risk of catching one.

New research shows that an antibiotic effective for bacterial pneumonia also appears to fight treatment-resistant staph infections. The drug is ceftobiprole. It appeared successful in fighting ...

Imagine a child with eczema who scratches a patch of irritated skin. A tiny opening forms, invisible to the eye. Into that breach slips a common bacterium, Staphylococcus aureus. For many people, the ...

YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), ...

YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody ...